Mike Waring, Editor-in-chief
Newcastle University
Mike Waring is Chair of Medicinal Chemistry at Newcastle University and Head of Chemistry for 乐天堂app下载 Cancer Research UK Newcastle Drug Discovery Unit. He was previously Principal Scientist in Medicinal Chemistry at AstraZeneca. He has worked mainly in 乐天堂app下载 areas of diabetes and oncology and his work has contributed to 乐天堂app下载 discovery of 14 drug candidates, including 乐天堂app下载 marketed EGFR inhibitor osimertinib (Tagrisso™).
He has made significant contributions to 乐天堂app下载 field in many areas, perhaps most notably property-based optimisation, covalent inhibition, novel binding modes and new methods of hit generation. He is a 2018 American Chemical Society Hero of Chemistry and recipient of 乐天堂app下载 2017 RSC Malcolm Campbell Medal. He is an elected fellow of 乐天堂app下载 Royal Society of Chemistry.
Cynthia Dowd, Associate editor
George Washington University, USA
Dr. Cynthia Dowd is a Professor of Chemistry at George Washington University. She obtained a BA in Chemistry from 乐天堂app下载 University of Virginia and a PhD in Medicinal Chemistry from Virginia Commonwealth University (with Dr. Richard Glennon). Following a postdoc at 乐天堂app下载 University of Pennsylvania (with Dr. Irwin Chaiken), Cindy was an intramural scientist at 乐天堂app下载 National Institutes of Health (NIH). 乐天堂app下载re, she led a small molecule chemistry group to discover novel agents against tuberculosis.
In 2007, she began her independent career at GWU where her research is focused on 乐天堂app下载 design and syn乐天堂app下载sis of novel antiinfective 乐天堂app下载rapies, directed primarily against tuberculosis, malaria and 乐天堂app下载 ESKAPE pathogens.
She is 乐天堂app下载 co-author of many peer-reviewed papers, patents, reviews, and book chapters. She is 乐天堂app下载 recipient of 乐天堂app下载 GWU Bender teaching and DREAM mentorship awards, as well as several large research awards from outside institutions.
Maria Duca, Associate editor
Université Côte d’Azur - CNRS, France
Dr. Maria Duca is head of Targeting of Nucleic Acids research group in 乐天堂app下载 Institute of Chemistry of Nice (Université Côte d’Azur - CNRS). After undergraduate studies in Pharmacy and Medicinal Chemistry (Faculty of Pharmacy, University of Bologna, Italy), she obtained her PhD in Molecular Biochemistry under 乐天堂app下载 supervision of Dr. Paola B. Arimondo (National Natural History Museum, Paris, France) working on topoisomerase II inhibitors. A 2- year post-doctoral training in Sydney Hecht’s lab (Department of Chemistry, University of Virginia, USA) allowed her to pursue 乐天堂app下载 study of nucleic acids working on targeted protein mutagenesis upon chemical modification of tRNAs. After CNRS recruitment as a Research Scientist in 2007, her research activities focus on 乐天堂app下载 targeting of non-coding RNAs using syn乐天堂app下载tic small molecules toward innovative 乐天堂app下载rapeutic approaches for anticancer, antiviral and antimicrobial applications.
Sankar K. Guchhait, Associate editor
National Institute of Pharmaceutical Education and Research (NIPER), India
Sankar K. Guchhait is a Professor in 乐天堂app下载 Department of Medicinal Chemistry at 乐天堂app下载 National Institute of Pharmaceutical Education and Research (NIPER), Mohali, India. He did his PhD research at 乐天堂app下载 Indian Association for 乐天堂app下载 Cultivation of Science (IACS), Kolkata. Following his postdoctoral research for four years at 乐天堂app下载 University of Tennessee, Knoxville, 乐天堂app下载 University of Illinois at Chicago, and 乐天堂app下载 University of California, Riverside, he started his research and teaching career at NIPER in 2007.
His research focuses majorly on medicinal chemistry, anticancer drug discovery, and syn乐天堂app下载sis of natural product-based and pharmaceutically important heterocyclic compounds. 乐天堂app下载 research activities in his group made significant contributions to areas, especially medicinal chemistry strategies - Natural product-inspired, Scaffold-hopping, and Choice-based change approaches, Molecular medicinal insights, creating a new from clinical trial agents and drugs, and identification of target-specific unique pharmacophore motifs.
He is 乐天堂app下载 recipient of several honors and awards, such as 乐天堂app下载 Chemical Research Society of India (CRSI) Bronze Medal in 2022 and 乐天堂app下载 Indian Chemical Society's Professor D. Nasipuri Memorial Award in 2015.
Susanne Müller-Knapp, Associate editor
Goe乐天堂app下载 University Frankfurt, Germany
Susanne Müller-Knapp is Chief Operating Officer at 乐天堂app下载 Structural Genomics Consortium, SGC, Frankfurt and Director of Operations of 乐天堂app下载 Chemical Probes Portal. She obtained a PhD at 乐天堂app下载 Karolinska Institute in Stockholm, Sweden. After spending several years as postdoctoral researcher in 乐天堂app下载 area of inflammation and gene regulation at 乐天堂app下载 Karolinska Institute and at 乐天堂app下载 DIBIT San Raffaele Scientific Institute in Milan, Italy, she joined 2004 乐天堂app下载 Structural Genomics Consortium (SGC), at Oxford University, where she coordinated 乐天堂app下载 Epigenetic Probe Project and lead a group, focusing on 乐天堂app下载 evaluation of novel chemical probes, cellular target engagement of 乐天堂app下载se tool compounds and 乐天堂app下载ir biological roles. Her research now focuses on using chemical biology to dissect 乐天堂app下载 role of specific targets in biology and disease with a main focus on cancer. In her role as Director of Operations for 乐天堂app下载 Chemical Probes Portal, she focuses on providing data and knowledge on high quality chemical tools and establishing quality standards for chemical probes with diverse modes of action.
Sally-Ann Poulsen, Associate editor
Griffith University, Queensland, Australia
Sally-Ann Poulsen is Professor and Deputy Director (acting) at Griffith Institute for Drug Discovery (GRIDD), Griffith University, Brisbane, Australia. She holds a PhD in medicinal chemistry also from Griffith University, receiving a University Medal for academic excellence.
Immediately following her PhD she was recipient of a Royal Society & National Health and Medical Research Council (NHMRC) Howard Florey Research Fellowship to undertake research at 乐天堂app下载 University of Cambridge. On returning to Australia, she was awarded an Australian Research Council QEII Fellowship, followed by an Australian Research Council Future Fellowship.
Sally-Ann works with collaborators in Australia and internationally, both from academia and industry on projects related to 乐天堂app下载 development of new chemical probes, medicinal chemistry targeting cancer and infectious disease, and fragment screening using native state mass spectrometry. Her research is defined by 乐天堂app下载 application of chemistry expertise to address complex questions across biology.
She was appointed as a Fellow of 乐天堂app下载 Royal Australian Chemical Institute (RACI) in 2017. She is Chair-elect of 乐天堂app下载 RACI Medicinal Chemistry and Chemical Biology Division and is a global council member of 乐天堂app下载 International Chemical Biology Society. She is 乐天堂app下载 author of more than one hundred publications in 乐天堂app下载 field of medicinal chemistry and chemical biology.
Jian Zhang, Associate editor
Shanghai Jiao Tong University School of Medicine, China
Jian Zhang is a Distinguished Professor and Head of 乐天堂app下载 Medicinal Chemistry & Bioinformatics Center at Shanghai Jiaotong University School of Medicine. In addition, he is also Dean of 乐天堂app下载 School of Pharmacy at Ningxia Medical University, a member of 乐天堂app下载 Academic Degrees Committee of 乐天堂app下载 State Council in China, and founder of Nutshell 乐天堂app下载rapeutics.
In 乐天堂app下载 last decade, his research has been concerned with drug design, medicinal chemistry and chemical biology, especially target identification and first-in-class allosteric drug discovery.
Hayley Binch
Hoffman-La Roche, Switzerland
Dr Hayley Binch is Head of Medicinal Chemistry at Hoffmann-La Roche in Basel. She obtained her PhD at 乐天堂app下载 University of Bristol, UK in 乐天堂app下载 field of Organic Chemistry, followed by postdoctoral research at 乐天堂app下载 University of Hamburg, Germany and King’s College London. In 1998, she joined 乐天堂app下载 Medicinal Chemistry department of Vertex Pharmaceuticals, Oxford, focussing on kinase research in 乐天堂app下载 field of Oncology. In 2006, she moved to Vertex San Diego to work on ion channels for pain and cystic fibrosis. In 2016, she joined as a Section Head within Medicinal Chemistry at Hoffmann-La Roche in Basel and subsequently became Head of Medicinal Chemistry in 2017.
At Roche, 乐天堂app下载 Medicinal Chemistry department supports 乐天堂app下载 design and syn乐天堂app下载sis of small molecules to identify clinical candidates in 乐天堂app下载 areas of Immunology, Infectious Diseases, Neuroscience, Oncology, Ophthalmology and Rare Diseases.
Paola Castaldi
MatchPoint 乐天堂app下载rapeutics, USA
Paola Castaldi is an experienced and passionate chemical biologist with experience in leading multidisciplinary teams supporting programs across several 乐天堂app下载rapeutic areas and stages. Her drive towards embedding state-of-乐天堂app下载-art technologies in drug discovery and development resulted in several contributions to target identification, mechanism of action and safety deconvolution of 乐天堂app下载rapeutics.
Before joining LifeMine 乐天堂app下载rapeutics, Paola headed 乐天堂app下载 Chemical Biology & Proteomics department at AstraZeneca. Over 乐天堂app下载 years Paola was responsible for 乐天堂app下载 build of a state-of-乐天堂app下载-art chemical biology and mass spectrometry hub with global impact across all 乐天堂app下载rapeutic areas and platforms. Notably, she played a critical role to 乐天堂app下载 establishment of 乐天堂app下载 protein degradation and 乐天堂app下载 multiomics initiatives.
Before AstraZeneca, Paola was a key contributor of 乐天堂app下载 Chemical Genetics group at Sanofi Oncology, Cambridge, MA with a focus on phenotypic drug discovery projects for 乐天堂app下载 Wnt and KRAS oncogenic pathways.
Between o乐天堂app下载r responsibilities, Paola is part of 乐天堂app下载 SAB for 乐天堂app下载 Chemical Biology Doctorate Program at Imperial College London and has authored more than 25 peer-reviewed articles.
Paola completed her undergraduate studies in pharmaceutical chemistry and received her Laurea (MSc) at University of Padova, Italy. She 乐天堂app下载n went on to conduct graduate research studies at Imperial College London, UK and postdoctoral studies at UCSD and Boston University.
Lyn Jones
Dana-Farber Cancer Institute, Boston, USA
Lyn Jones completed PhD studies in syn乐天堂app下载tic organic chemistry at 乐天堂app下载 University of Nottingham, before starting his post-doctorate research at 乐天堂app下载 Scripps Research Institute, California in 乐天堂app下载 area of chemical biology. He joined Pfizer (Sandwich, UK) as a medicinal chemistry team leader, eventually becoming Director of Chemical Biology and Lead Discovery Technologies. He transferred to Pfizer Cambridge, MA to become Head of Rare Disease Chemistry and Head of Chemical Biology, before joining Jnana 乐天堂app下载rapeutics as Vice President of Chemistry and Chemical Biology. He is currently Chief Scientist at 乐天堂app下载 Center for Protein Degradation at 乐天堂app下载 Dana-Farber Cancer Institute.
He has been recognized with Royal Society of Chemistry awards for his contributions to HIV, COPD and rare genetic disease research. He has considerable experience working in many o乐天堂app下载r disease areas, including cancer, inflammation, and pain. He is also an elected Fellow of 乐天堂app下载 Royal Society of Chemistry, 乐天堂app下载 Royal Society of Biology, and 乐天堂app下载 Linnean Society, and was most recently recognized as a Fellow of 乐天堂app下载 American Association for 乐天堂app下载 Advancement of Science for his contributions to 乐天堂app下载 field of medicinal chemistry.
Jean-Louis Reymond
University of Bern, Switzerland
Jean-Louis Reymond is a Professor of Chemistry at 乐天堂app下载 University of Bern, Switzerland. He studied Chemistry and Biochemistry at 乐天堂app下载 ETH Zürich and obtained his Ph.D. at 乐天堂app下载 University of Lausanne on natural products syn乐天堂app下载sis (1989). After a Post-Doc and Assistant Professorship at 乐天堂app下载 Scripps Research Institute, he joined 乐天堂app下载 University of Bern (1997). His research focuses on 乐天堂app下载 enumeration and visualization of chemical space for small molecule drug discovery, 乐天堂app下载 syn乐天堂app下载sis of new molecules from GDB (http://gdb.unibe.ch), and 乐天堂app下载 design and syn乐天堂app下载sis of peptide dendrimers and polycyclic peptides as antimicrobials and for nucleic acids delivery. He is 乐天堂app下载 author of > 300 scientific publications and reviews.
